A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma

Supportive Care in Cancer

Volumn 23, Issue 6, 2015, Pages 1503-1512

  Berenson, James R ^a,b,c   Yellin, Ori ^a,k   Shamasunder, Hesaraghatta K ^d   Chen, Chien Shing ^e   Charu, Veena ^f   Woliver, Thomas B ^g   Sanani, Shamel ^h   Schlutz, Michael ⁱ   Nassir, Youram ^b   Swift, Regina A ^b   Andreu Vieyra, Claudia ^a   Vescio, Robert ^j  

^a Oncotherapeutics   (United States)

^b MD   (United States)

^c INSTITUTE FOR MYELOMA AND BONE CANCER RESEARCH   (United States)

^d Antelope Valley Cancer Center   (United States)

^e LOMA LINDA UNIVERSITY   (United States)

^f Pacific Cancer Medical Center   (United States)

^g Santa Barbara Hematology Oncology   (United States)

^h Notrelli Hematology and Oncology   (United States)

ⁱ Cedars Sinai Medical Center ^*  (United States)

^j CEDARS SINAI MEDICAL CENTER   (United States)

^k GILEAD SCIENCES   (United States)

more..

Author keywords

Armodafinil; Cancer related fatigue; Cognitive function; Myeloma; Phase 3

Indexed keywords

ARMODAFINIL; BENZHYDRYL DERIVATIVE; WAKEFULNESS PROMOTING AGENT;

ADULT; AGED; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; FATIGUE; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE MYELOMA; PHASE 3 CLINICAL TRIAL; PLACEBO EFFECT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; WAKEFULNESS;

ADULT; AGED; BENZHYDRYL COMPOUNDS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLACEBO EFFECT; QUALITY OF LIFE; WAKEFULNESS; WAKEFULNESS-PROMOTING AGENTS;

EID: 84939946592     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-014-2486-7     Document Type: Article

References (46)

1. Pozzi S, Marcheselli L, Bari A et al (2013) Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis. Br J Haematol 163:40–46. doi:10.1111/bjh.12465
2. Schaapveld M, Visser O, Siesling S et al (2010) Improved survival among younger but not among older patients with multiple myeloma in the Netherlands, a population-based study since 1989. Eur J Cancer 46:160–169. doi:10.1016/j.ejca.2009.07.006
3. Kumar SK, Rajkumar SV, Dispenzieri A et al (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516–2520. doi:10.1182/blood-2007-10-116129
4. Chanan-Khan A, Miller KC (2006) Supportive care in multiple myeloma. Clin Lymphoma Myeloma 7:42–50. doi:10.3816/CLM.2006.n.038
5. Gulbrandsen N, Hjermstad MJ, Wisløff F (2004) Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences. Eur J Haematol 72:172–180. doi:10.1046/j.0902-4441.2003.00195.x
6. Sherman AC, Simonton S, Latif U et al (2004) Psychosocial adjustment and quality of life among multiple myeloma patients undergoing evaluation for autologous stem cell transplantation. Bone Marrow Transplant 33:955–962. doi:10.1038/sj.bmt.1704465
7. Johnsen AT, Tholstrup D, Petersen MA et al (2009) Health related quality of life in a nationally representative sample of haematological patients. Eur J Haematol 83:139–148. doi:10.1111/j.1600-0609.2009.01250.x
8. Sherman AC, Simonton S, Latif U et al (2009) Changes in quality-of-life and psychosocial adjustment among multiple myeloma patients treated with high-dose melphalan and autologous stem cell transplantation. Biol Blood Marrow Transplant 15:12–20. doi:10.1016/j.bbmt.2008.09.023
9. Siegel D, Martin T, Nooka A et al (2013) Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 98:1753–1761. doi:10.3324/haematol.2013.089334
10. Ludwig H, Pohl G, Osterborg A (2004) Anemia in multiple myeloma. Clin Adv Hematol Oncol 2:233–241
11. Cella D (1997) The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34:13–19
12. Glaspy J, Degos L, Dicato M, Demetri GD (2002) Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum- and nonplatinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials. Oncologist 7:126–135
13. Dvorak C (2006) Common complaints, difficult diagnosis: multiple myeloma. J Am Acad Nurse Pract 18:190–194. doi:10.1111/j.1745-7599.2006.00122.x
14. Pertl MM, Quigley J, Hevey D (2014) “I’m not complaining because I’m alive”: barriers to the emergence of a discourse of cancer-related fatigue. Psychol Health 29:141–161. doi:10.1080/08870446.2013.839792
15. Barsevick AM, Irwin MR, Hinds P et al (2013) Recommendations for high-priority research on cancer-related fatigue in children and adults. J Natl Cancer Inst 105:1432–1440. doi:10.1093/jnci/djt242
16. Minton O, Berger A, Barsevick A et al (2013) Cancer-related fatigue and its impact on functioning. Cancer 119 Suppl:2124–2130. doi:10.1002/cncr.28058
17. Bortolon C, Krikorian A, Carayol M et al (2014) Cancer-related fatigue in breast cancer patients after surgery: a multicomponent model using partial least squares-path modeling. Psychooncology 23:444–451. doi:10.1002/pon.3438
18. Glaus A, Crow R, Hammond S (1996) A qualitative study to explore the concept of fatigue/tiredness in cancer patients and in healthy individuals. Support Care Cancer 4:82–96
19. Rönnbäck L, Hansson E (2004) On the potential role of glutamate transport in mental fatigue. J Neuroinflammation 1:22. doi:10.1186/1742-2094-1-22
20. Finnegan-John J, Molassiotis A, Richardson A, Ream E (2013) A systematic review of complementary and alternative medicine interventions for the management of cancer-related fatigue. Integr Cancer Ther 12:276–290. doi:10.1177/1534735413485816
21. Breitbart W, Alici Y (2008) Pharmacologic treatment options for cancer-related fatigue: current state of clinical research. Clin J Oncol Nurs 12:27–36. doi:10.1188/08.CJON. S2.27-36
22. Blackhall L, Petroni G, Shu J et al (2009) A pilot study evaluating the safety and efficacy of modafinal for cancer-related fatigue. J Palliat Med 12:433–439. doi:10.1089/jpm.2008.0230
23. Kaleita TA, Wellisch DK, Graham CA, Steh B, Nghiemphu P, Ford JM, Lai A, Peak S, Cloughesy T (2006) Pilot study of modafinil for treatment of neurobehavioral dysfunction and fatigue in adult patients with brain tumors. J Clin Oncol 24:1503
24. Rabkin JG, McElhiney MC, Rabkin R Treatment of HIV-related fatigue with armodafinil: a placebo-controlled randomized trial. Psychosomatics 52:328–6. doi:10.1016/j.psym.2011.02.005
25. Durie BG (1986) Staging and kinetics of multiple myeloma. Semin Oncol 13:300–309
26. Cella D, Peterman A, Passik S et al (1998) Progress toward guidelines for the management of fatigue. Oncology (Williston Park) 12:369–377
27. Cella D, Davis K, Breitbart W, Curt G (2001) Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol 19:3385–3391
28. Chang YJ, Lee JS, Lee CG et al (2007) Assessment of clinical relevant fatigue level in cancer. Support Care Cancer 15:891–896. doi:10.1007/s00520-007-0219-x
29. Howard R, Roth T, Drake CL (2014) The effects of armodafinil on objective sleepiness and performance in a shift work disorder sample unselected for objective sleepiness. J Clin Psychopharmacol 34:369–373. doi:10.1097/JCP.0000000000000136
30. Carroll BT, Kathol RG, Noyes R et al (1993) Screening for depression and anxiety in cancer patients using the Hospital Anxiety and Depression Scale. Gen Hosp Psychiatry 15:69–74
31. Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14:540–545
32. Davies AD (1968) The influence of age on trail making test performance. J Clin Psychol 24:96–98
33. Smith A (1968) Symbol digits modalities test Los Angeles: western psychological services. In: Helmuth J (ed) Learning disorders. Special Child Publications, Seattle, pp 83–91
34. Yellen SB, Cella DF, Webster K et al (1997) Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manag 13:63–74
35. Colameco S, Coren JS (2009) Opioid-induced endocrinopathy. J Am Osteopath Assoc 109:20–25
36. Paltiel O, Marzec-boguslawska A, Soskolne V et al (2004) Use of tranquilizers and sleeping pills among cancer patients is associated with a poorer quality of life. Qual Life Res 13:1699–1706
37. Minton O, Richardson A, Sharpe M et al (2010) Drug therapy for the management of cancer-related fatigue. Cochrane database Syst Rev CD006704. doi:10.1002/14651858.CD006704.pub3
38. Möller F, Poettgen J, Broemel F et al (2011) HAGIL (Hamburg Vigil Study): a randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis. Mult Scler 17:1002–1009. doi:10.1177/1352458511402410
39. Spathis A, Fife K, Blackhall F, et al (2014) Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial. J Clin Oncol 32:1882–1888
40. Boele FW, Douw L, de Groot M et al (2013) The effect of modafinil on fatigue, cognitive functioning, and mood in primary brain tumor patients: a multicenter randomized controlled trial. Neuro Oncol 15:1420–1428. doi:10.1093/neuonc/not102
41. Hovey E, de Souza P, Marx G et al (2014) Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy. Support Care Cancer 22:1233–1242. doi:10.1007/s00520-013-2076-0
42. Kohli S, Fisher SG, Tra Y et al (2009) The effect of modafinil on cognitive function in breast cancer survivors. Cancer 115:2605–2616. doi:10.1002/cncr.24287
43. Stone P, Richards M, A’Hern R, Hardy J (2000) A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Ann Oncol 11:561–567
44. Seyidova-Khoshknabi D, Davis MP, Walsh D (2011) Review article: a systematic review of cancer-related fatigue measurement questionnaires. Am J Hosp Palliat Care 28:119–129. doi:10.1177/1049909110381590
45. Coleman EA, Goodwin JA, Coon SK et al (2011) Fatigue, sleep, pain, mood, and performance status in patients with multiple myeloma. Cancer Nurs 34:219–227. doi:10.1097/NCC.0b013e3181f9904d
46. Roth T, White D, Schmidt-Nowara W et al (2006) Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults. Clin Ther 28:689–706. doi:10.1016/j.clinthera.2006.05.013